title: Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?
authors.forename: Eitan
authors.initials: E
authors.lastname: Amir
authors.forename: Bostjan
authors.initials: B
authors.lastname: Seruga
authors.forename: Orit
authors.initials: O
authors.lastname: Freedman
authors.forename: Ian
authors.initials: I
authors.lastname: Tannock
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D000077341:Lapatinib; D017239:Paclitaxel / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage
chemical_list: D011799:Quinazolines; D000077341:Lapatinib; D017239:Paclitaxel